Journal Browser

Journal Browser

The Potential Roles of Natural Active Products in Neurological Disorders

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 2495

Special Issue Editor

E-Mail Website
Guest Editor
Laboratory of Preclinical Testing, Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, Lublin, Poland
Interests: depression; anxiety; behavioral studies; epilepsy; cannabinoid receptors; antidepressant drugs

Special Issue Information

Dear Colleagues,

According to global statistics, over 320 million people suffer from depressive disorders, and this number is still growing, partially as one of the post-COVID-19 pandemic effects. Depressive disorders are frequently accompanied by other diseases, including epilepsy. More than 23% and 13% of adult and pediatric patients with epilepsy, respectively, are concurrently diagnosed with depression. It has also been demonstrated that people suffering from depression have a significantly higher risk of developing epilepsy. Unfortunately, management of both depression and epilepsy is difficult, and comorbidity of these two diseases further reduces treatment effectiveness, which results in an elevated risk of depressive/epileptic episodes, or increased seizure severity. Generally, about 40% of depressive patients do not respond to antidepressant therapy, and ca. 60% of people who take antidepressant drugs do not achieve a complete remission. Furthermore, up to 50–85% of patients with depression experience relapse of the disease. Similarly, about 30% of patients with epilepsy are resistant to currently available drugs. Therapy with antidepressants and antiepileptics may induce bothersome side effects and it may interact with other substances, which may further negatively affect the effectiveness of treatment. Therefore, scientists are searching for novel strategies for the management of depressive disorders and epilepsy. 

Natural products as substances characterized by diversity and structural complexity have gained recently particular attention. Natural active products are considered less toxic and better tolerated than synthetic drugs. More interest in natural products or compounds has been increasing, and various studies on their efficacy and molecular biological mechanisms have been conducted. Natural active products can serve as substitutes for existing drugs and have the result of further enhancing the therapeutic effect. They can be taken as adjuvants to conventional therapy as well.

Our Special Issue will focus on the therapeutic or inhibiting roles of natural active products in depression and epilepsy, we would like to bring together experts working in the field of these two medical conditions and invite them to work on molecular or cellular mechanisms, potential benefits related to the natural products in the treatment of depressive disorders and seizures. We encourage people to submit research articles or original reviews on all aspects of the molecular and cellular mechanisms modulated by natural products. Importantly, pure clinical studies will not be suitable for our special issue, but clinical research or pure model submissions together with biomolecular experiments or data are welcomed.

Dr. Anna D. Serefko
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • natural active products
  • phytochemicals
  • bioactive compounds
  • Neurological Disorders
  • depressive disorders
  • Parkinson's disease
  • depressive/epileptic episodes
  • antidepressants and antiepileptics
  • Alzheimer's disease
  • brain stroke
  • molecular mechanism
  • drug delivery
  • therapeutic potentials
  • structure-activity relationships
  • advanced therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 537 KiB  
Caffeine and Its Interactions with Antiseizure Medications—Is There a Correlation between Preclinical and Clinical Data?
by Barbara Miziak, Barbara Błaszczyk, Magdalena Chrościńska-Krawczyk and Stanisław J. Czuczwar
Int. J. Mol. Sci. 2023, 24(24), 17569; https://doi.org/10.3390/ijms242417569 - 17 Dec 2023
Cited by 2 | Viewed by 2096
Experimental studies reveal that caffeine (trimethylxanthine) at subconvulsive doses, distinctly reduced the anticonvulsant activity of numerous antiseizure medications (ASMs) in rodents, oxcarbazepine, tiagabine and lamotrigine being the exceptions. Clinical data based on low numbers of patients support the experimental results by showing that [...] Read more.
Experimental studies reveal that caffeine (trimethylxanthine) at subconvulsive doses, distinctly reduced the anticonvulsant activity of numerous antiseizure medications (ASMs) in rodents, oxcarbazepine, tiagabine and lamotrigine being the exceptions. Clinical data based on low numbers of patients support the experimental results by showing that caffeine (ingested in high quantities) may sharply increase seizure frequency, considerably reducing the quality of patients’ lives. In contrast, this obviously negative activity of caffeine was not found in clinical studies involving much higher numbers of patients. ASMs vulnerable to caffeine in experimental models of seizures encompass carbamazepine, phenobarbital, phenytoin, valproate, gabapentin, levetiracetam, pregabalin and topiramate. An inhibition of R-calcium channels by lamotrigine and oxcarbazepine may account for their resistance to the trimethylxanthine. This assumption, however, is complicated by the fact that topiramate also seems to be a blocker of R-calcium channels. A question arises why large clinical studies failed to confirm the results of experimental and case-report studies. A possibility exists that the proportion of patients taking ASMs resistant to caffeine may be significant and such patients may be sufficiently protected against the negative activity of caffeine. Full article
Show Figures

Figure 1

Back to TopTop